Leeds Institute of Molecular Medicine, St. James's University Hospital, Beckett Street, Leeds, UK.
Br J Pharmacol. 2009 Aug;157(7):1172-4. doi: 10.1111/j.1476-5381.2009.00286.x.
The bane of anti-cancer therapy is usually the development of resistance to apoptosis in malignant cells. Identification of strategies to re-sensitize cancer cells to apoptosis has now become a top priority in anti-cancer research. Denbinobin is a novel, naturally occurring phenathroquinone isolated from orchids of the genus Dendrobium that has remarkable anti-cancer activities demonstrated both in vitro and in vivo. Recently denbinobin has been shown to diminish the levels of expression of the decoy receptor-3 and also to act synergistically with Fas ligand to induce apoptosis in a pancreatic adenocarcinoma cell line. There is hope that denbinobin could be developed as an adjuvant in combination therapies aimed at killing cancers that rely on decoy receptors to evade the host's immune surveillance.
癌症治疗的难题通常是恶性细胞对细胞凋亡的抗性的发展。现在，确定使癌细胞重新对细胞凋亡敏感的策略已成为癌症研究的重中之重。冬凌草甲素是一种从兰科石斛属植物中分离出来的新型天然苯并醌，具有显著的体外和体内抗癌活性。最近的研究表明，冬凌草甲素可以降低诱饵受体 3 的表达水平，并与 Fas 配体协同作用，诱导胰腺腺癌细胞系凋亡。人们希望冬凌草甲素能够被开发为联合治疗的辅助药物，旨在杀死那些依赖诱饵受体逃避宿主免疫监视的癌症。
